 |
||||
| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
|
||||
| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
*INSERM U.489, Hôpital Tenon, Paris; and AP-HP, Laboratoire de Physiologie, UFR St Antoine, Paris, France.
Correspondence to Dr. Christos Chatziantoniou, INSERM U.489, Hôpital Tenon, 75020 Paris, France. Phone: 331-56-01-66-58; Fax: 331-43-64-54-48;
ABSTRACT. Renal fibrosis is one of the major complications associated with the development of hypertension. The objective of the present study was to determine whether and by which mechanisms treatment with AT1 receptor antagonists makes possible the regression of renal vascular and glomerular fibrosis. Experiments were performed in the hypertensive model of nitric oxide (NO) deficiency in rats. After 4 wk of hypertension, mortality rates averaged 20%; the surviving animals displayed a decline of renal function (urine protein/creatinine, 1.89 ± 0.63 versus 0.24 ± 0.03 mg/mmol; creatininemia, 110 ± 14 versus 38 ± 2 mmol/L in hypertensive animals and control, respectively; P < 0.01) and an exaggerated gene and protein expression of TGF-
, collagen I, and collagen IV (P < 0.001) within the renal vasculature associated with the development of glomerulosclerosis (sclerotic index, 2.26 ± 0.29 versus 0.12 ± 0.04; P < 0.001). In addition, activities of matrix metalloproteinases 2 and 9 were increased twofold in renal vessels and glomeruli (P < 0.01). Afterwards, losartan, an antagonist of angiotensin receptor type I, or hydralazine were administered in subgroups of hypertensive animals. After 1 wk of angiotensin II antagonism, collagen I, collagen IV, and TGF- gene and protein expressions were decreased and glomerulosclerosis was less marked (sclerotic index 1.04 ± 0.45), whereas activities of metalloproteinases remained twofold higher than controls (P < 0.01). Hydralazine failed to improve renal function despite a similar degree of systolic pressure decrease. After 4 wk of losartan, the renal functional and histologic parameters were completely normalized, whereas they remained damaged in the hypertensive animals in which the mortality rate reached 85%. These data suggest that the progression of renal vascular fibrosis is a reversible process, at least in the NO deficiency model. The mechanism of the regression appears to be dual: inhibition of collagen synthesis due to AT1 receptor antagonism and activation of metalloproteinases that is probably associated with the degree of fibrosis independently of AT1 blockade. E-mail: christos.chatziantoniou@tnn.ap-hop-paris.fr
This article has been cited by other articles:
 |
|
 |
|
  K. Katayama, M. Kawano, I. Naito, H. Ishikawa, Y. Sado, N. Asakawa, T. Murata, K. Oosugi, M. Kiyohara, E. Ishikawa, et al. Irradiation Prolongs Survival of Alport Mice J. Am. Soc. Nephrol., September 1, 2008; 19(9): 1692 - 1700. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Xia, E. Seckin, Y. Xiang, M. Vranesic, W. B. Mathews, K. Hong, D. A. Bluemke, L. O. Lerman, and Z. Szabo Positron-Emission Tomography Imaging of the Angiotensin II Subtype 1 Receptor in Swine Renal Artery Stenosis Hypertension, February 1, 2008; 51(2): 466 - 473. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. van de Wal, P. van der Harst, W. B. Gerritsen, F. van der Horst, T. H. Plokker, R. T Gansevoort, W. H van Gilst, and A. A Voors Plasma matrix metalloproteinase-9 and ACE-inhibitor-induced improvement of urinary albumin excretion in non-diabetic, microalbuminuric subjects Journal of Renin-Angiotensin-Aldosterone System, December 1, 2007; 8(4): 177 - 180. [Abstract] [PDF]
|
|
|
|
|
|
Y. Matsumoto, S. Ueda, S.-i. Yamagishi, K. Matsuguma, R. Shibata, K. Fukami, H. Matsuoka, T. Imaizumi, and S. Okuda Dimethylarginine Dimethylaminohydrolase Prevents Progression of Renal Dysfunction by Inhibiting Loss of Peritubular Capillaries and Tubulointerstitial Fibrosis in a Rat Model of Chronic Kidney Disease J. Am. Soc. Nephrol., May 1, 2007; 18(5): 1525 - 1533. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Flamant, S. Placier, A. Rodenas, C. A. Curat, W. F. Vogel, C. Chatziantoniou, and J.-C. Dussaule Discoidin Domain Receptor 1 Null Mice Are Protected against Hypertension-Induced Renal Disease J. Am. Soc. Nephrol., December 1, 2006; 17(12): 3374 - 3381. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Opocensky, H. J. Kramer, A. Backer, Z. Vernerova, V. Eis, L. Cervenka, V. Certikova Chabova, V. Tesar, and I. Vaneckova Late-Onset Endothelin-A Receptor Blockade Reduces Podocyte Injury in Homozygous Ren-2 Rats Despite Severe Hypertension Hypertension, November 1, 2006; 48(5): 965 - 971. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. A. Khan, H. Farhangkhoee, J. L. Mahon, L. Bere, J. R. Gonder, B. M. Chan, S. Uniyal, and S. Chakrabarti Endothelins: regulators of extracellular matrix protein production in diabetes. Experimental Biology and Medicine, June 1, 2006; 231(6): 1022 - 1029. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Wang, X. R. Huang, E. Canlas, K. Oka, L. D. Truong, C. Deng, N. A. Bhowmick, W. Ju, E. P. Bottinger, and H. Y. Lan Essential Role of Smad3 in Angiotensin II-Induced Vascular Fibrosis Circ. Res., April 28, 2006; 98(8): 1032 - 1039. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Placier, J.-J. Boffa, J.-C. Dussaule, and C. Chatziantoniou Reversal of renal lesions following interruption of nitric oxide synthesis inhibition in transgenic mice Nephrol. Dial. Transplant., April 1, 2006; 21(4): 881 - 888. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. K. Fujihara, C. R. Sena, D. M. A. C. Malheiros, A. L. Mattar, and R. Zatz Short-term nitric oxide inhibition induces progressive nephropathy after regression of initial renal injury Am J Physiol Renal Physiol, March 1, 2006; 290(3): F632 - F640. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. B. Fogo Progression versus regression of chronic kidney disease Nephrol. Dial. Transplant., February 1, 2006; 21(2): 281 - 284. [Full Text] [PDF]
|
|
|
|
|
|
M. Eikmans, J. A. Aben, K. Koop, H. J. Baelde, E. de Heer, and J. A. Bruijn Genetic factors in progressive renal disease: the good ones, the bad ones and the ugly ducklings Nephrol. Dial. Transplant., February 1, 2006; 21(2): 257 - 260. [Full Text] [PDF]
|
|
|
|
|
|
C. C.-c. Hsu, M. S. Bray, W.H.L. Kao, J. S. Pankow, E. Boerwinkle, and J. Coresh Genetic Variation of the Renin-Angiotensin System and Chronic Kidney Disease Progression in Black Individuals in the Atherosclerosis Risk in Communities Study J. Am. Soc. Nephrol., February 1, 2006; 17(2): 504 - 512. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Bolbrinker, S. Markovic, M. Wehland, W. B. W. H. Melenhorst, H. van Goor, and R. Kreutz Expression and Response to Angiotensin-Converting Enzyme Inhibition of Matrix Metalloproteinases 2 and 9 in Renal Glomerular Damage in Young Transgenic Rats with Renin-Dependent Hypertension J. Pharmacol. Exp. Ther., January 1, 2006; 316(1): 8 - 16. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Wolf Zenon's paradox or how much to lower blood pressure for optimal renoprotection Nephrol. Dial. Transplant., November 1, 2005; 20(11): 2304 - 2307. [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Faulkner, L. M. Szcykalski, F. Springer, and J. L. Barnes Origin of Interstitial Fibroblasts in an Accelerated Model of Angiotensin II-Induced Renal Fibrosis Am. J. Pathol., November 1, 2005; 167(5): 1193 - 1205. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Chatziantoniou and J.-C. Dussaule Insights into the mechanisms of renal fibrosis: is it possible to achieve regression? Am J Physiol Renal Physiol, August 1, 2005; 289(2): F227 - F234. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Ishizaka, K. Saito, E. Noiri, M. Sata, H. Ikeda, A. Ohno, J. Ando, I. Mori, M. Ohno, and R. Nagai Administration of ANG II induces iron deposition and upregulation of TGF-{beta}1 mRNA in the rat liver Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2005; 288(4): R1063 - R1070. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Zareie, E. D. Keuning, P. M. ter Wee, R. H. J. Beelen, and J. van den Born Peritoneal dialysis fluid-induced changes of the peritoneal membrane are reversible after peritoneal rest in rats Nephrol. Dial. Transplant., January 1, 2005; 20(1): 189 - 193. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Khanna, M. S. Plummer, G. Hilton, G. M. Pieper, and S. Ledbetter Anti-Transforming Growth Factor Antibody at Low but Not High Doses Limits Cyclosporine-Mediated Nephrotoxicity Without Altering Rat Cardiac Allograft Survival: Potential of Therapeutic Applications Circulation, December 21, 2004; 110(25): 3822 - 3829. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Adamczak, M.-L. Gross, K. Amann, and E. Ritz Reversal of Glomerular Lesions Involves Coordinated Restructuring of Glomerular Microvasculature J. Am. Soc. Nephrol., December 1, 2004; 15(12): 3063 - 3072. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Ortmann, K. Amann, R. P. Brandes, M. Kretzler, K. Munter, N. Parekh, T. Traupe, M. Lange, T. Lattmann, and M. Barton Role of Podocytes for Reversal of Glomerulosclerosis and Proteinuria in the Aging Kidney After Endothelin Inhibition Hypertension, December 1, 2004; 44(6): 974 - 981. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Okada, Y. Watanabe, T. Kikuta, T. Kobayashi, Y. Kanno, T. Sugaya, and H. Suzuki Bradykinin Decreases Plasminogen Activator Inhibitor-1 Expression and Facilitates Matrix Degradation in the Renal Tubulointerstitium under Angiotensin-Converting Enzyme Blockade J. Am. Soc. Nephrol., September 1, 2004; 15(9): 2404 - 2413. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Abbate and G. Remuzzi Can We Really Lessen Kidney Damage to the Point that the Loss of Renal Function of Progressive Nephropathy May Revert? J. Am. Soc. Nephrol., May 1, 2003; 14(5): 1411 - 1414. [Full Text] [PDF]
|
|
|
HOME
CURRENT ISSUE
ARCHIVES
JASN Express
ONLINE SUBMISSION
AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP |
Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673
